Does the media favor ASND or CELC?

In the previous week, Ascendis Pharma A/S had 17 more articles in the media than Celcuity. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.68 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 7 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SMMT or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is SMMT or CELC more profitable?

Summit Therapeutics' return on equity of -168.94% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Celcuity N/A -350.78% -41.54%

Does the media refer more to SMMT or CELC?

In the previous week, Summit Therapeutics had 1 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.20 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, EXEL or CELC?

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.23 $782.57M $3.18 18.35 Celcuity N/A N/A -$177.04M -$4.30 N/A

Is EXEL or CELC more profitable?

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Celcuity N/A -350.78% -41.54%

Does the media favor EXEL or CELC?

In the previous week, Exelixis had 8 more articles in the media than Celcuity. MarketBeat recorded 14 mentions for Exelixis and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Exelixis' score of 0.44 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CELC or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for BridgeBio Pharma and 6 mentions for Celcuity. BridgeBio Pharma's average media sentiment score of 0.87 beat Celcuity's score of 0.83 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or CELC?

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.64 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Celcuity (CELC) Competitors

$80.61 -4.30 (-5.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$81.08 +0.47 (+0.58%)

As of 09/18/2026 07:54 PM Eastern

Compare

CELC vs. ASND, SMMT, EXEL, BBIO, and BMRN

Should you buy Celcuity stock or one of its competitors? Celcuity's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), Exelixis (EXEL), BridgeBio Pharma (BBIO), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celcuity compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Ascendis Pharma A/S had 17 more articles in the media than Celcuity. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Ascendis Pharma A/S's score of 0.68 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

63.3% of Celcuity shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Celcuity has lower revenue, but higher earnings than Ascendis Pharma A/S. Celcuity is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Celcuity's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Celcuity	N/A	-350.78%	-41.54%

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $310.75, indicating a potential upside of 31.27%. Celcuity has a consensus price target of $154.75, indicating a potential upside of 91.97%. Given Celcuity's higher probable upside, analysts plainly believe Celcuity is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Ascendis Pharma A/S beats Celcuity on 12 of the 16 factors compared between the two stocks.

How does Celcuity compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Summit Therapeutics had 1 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Summit Therapeutics' score of 0.20 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Summit Therapeutics presently has a consensus price target of $25.91, indicating a potential upside of 45.14%. Celcuity has a consensus price target of $154.75, indicating a potential upside of 91.97%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summit Therapeutics' return on equity of -168.94% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Celcuity	N/A	-350.78%	-41.54%

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Summary

Celcuity beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Celcuity compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Celcuity	N/A	-350.78%	-41.54%

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.35
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Exelixis had 8 more articles in the media than Celcuity. MarketBeat recorded 14 mentions for Exelixis and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat Exelixis' score of 0.44 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Exelixis currently has a consensus target price of $50.29, suggesting a potential downside of 13.84%. Celcuity has a consensus target price of $154.75, suggesting a potential upside of 91.97%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Exelixis beats Celcuity on 11 of the 16 factors compared between the two stocks.

How does Celcuity compare to BridgeBio Pharma?

Celcuity (NASDAQ:CELC) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Celcuity has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Celcuity has higher earnings, but lower revenue than BridgeBio Pharma. Celcuity is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A

63.3% of Celcuity shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celcuity presently has a consensus price target of $154.75, suggesting a potential upside of 91.97%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 54.05%. Given Celcuity's stronger consensus rating and higher possible upside, equities research analysts plainly believe Celcuity is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 2 more articles in the media than Celcuity. MarketBeat recorded 8 mentions for BridgeBio Pharma and 6 mentions for Celcuity. BridgeBio Pharma's average media sentiment score of 0.87 beat Celcuity's score of 0.83 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Celcuity on 10 of the 15 factors compared between the two stocks.

How does Celcuity compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Celcuity's net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Celcuity	N/A	-350.78%	-41.54%

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 5 more articles in the media than Celcuity. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 6 mentions for Celcuity. Celcuity's average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.64 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical presently has a consensus price target of $89.17, suggesting a potential upside of 39.46%. Celcuity has a consensus price target of $154.75, suggesting a potential upside of 91.97%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

BioMarin Pharmaceutical has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Summary

BioMarin Pharmaceutical beats Celcuity on 12 of the 16 factors compared between the two stocks.

Get Celcuity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELC vs. The Competition

Export

Metric	Celcuity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.15B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-18.75	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	37.15	15.45	10.46	6.33
Net Income	-$177.04M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-3.40%	-1.21%	0.59%	1.12%
1 Month Performance	-13.91%	-4.42%	-2.01%	-2.67%
1 Year Performance	55.38%	37.81%	18.09%	6.01%

Celcuity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELC Celcuity	2.9871 of 5 stars	$80.61 -5.1%	$154.75 +92.0%	+46.5%	$4.15B	N/A	N/A	155	News Coverage Analyst Forecast
ASND Ascendis Pharma A/S	4.7241 of 5 stars	$230.89 -12.8%	$310.80 +34.6%	+18.7%	$14.42B	$814.57M	17.93	1,189	Analyst Downgrade
SMMT Summit Therapeutics	2.3302 of 5 stars	$17.45 -5.3%	$25.91 +48.5%	-7.2%	$13.93B	N/A	N/A	265
EXEL Exelixis	2.4963 of 5 stars	$55.61 -1.1%	$50.07 -10.0%	+44.3%	$13.77B	$2.44B	17.48	1,077	Positive News
BBIO BridgeBio Pharma	3.5816 of 5 stars	$67.78 -6.4%	$102.61 +51.4%	+24.9%	$13.29B	$713.07M	N/A	839	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celcuity (CELC) Competitors

CELC vs. ASND, SMMT, EXEL, BBIO, and BMRN

How does Celcuity compare to Ascendis Pharma A/S?

Summary

How does Celcuity compare to Summit Therapeutics?

Summary

How does Celcuity compare to Exelixis?

Summary

How does Celcuity compare to BridgeBio Pharma?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celcuity (CELC) Competitors

CELC vs. ASND, SMMT, EXEL, BBIO, and BMRN

How does Celcuity compare to Ascendis Pharma A/S?

Does the media favor ASND or CELC?

Do institutionals and insiders have more ownership in ASND or CELC?

Which has stronger valuation and earnings, ASND or CELC?

Is ASND or CELC more profitable?

Which has more volatility and risk, ASND or CELC?

Do analysts prefer ASND or CELC?

Summary

How does Celcuity compare to Summit Therapeutics?

Does the media refer more to SMMT or CELC?

Which has preferable valuation & earnings, SMMT or CELC?

Do analysts recommend SMMT or CELC?

Is SMMT or CELC more profitable?

Do institutionals & insiders believe in SMMT or CELC?

Which has more volatility and risk, SMMT or CELC?

Summary

How does Celcuity compare to Exelixis?

Do institutionals and insiders hold more shares of EXEL or CELC?

Is EXEL or CELC more profitable?

Which has preferable earnings & valuation, EXEL or CELC?

Does the media favor EXEL or CELC?

Which has more risk and volatility, EXEL or CELC?

Do analysts rate EXEL or CELC?

Summary

How does Celcuity compare to BridgeBio Pharma?

Is CELC or BBIO more profitable?

Which has higher earnings & valuation, CELC or BBIO?

Do institutionals & insiders hold more shares of CELC or BBIO?

Do analysts rate CELC or BBIO?

Does the media prefer CELC or BBIO?

Which has more risk & volatility, CELC or BBIO?

Summary

How does Celcuity compare to BioMarin Pharmaceutical?

Do insiders & institutionals hold more shares of BMRN or CELC?

Is BMRN or CELC more profitable?

Which has more risk & volatility, BMRN or CELC?

Does the media favor BMRN or CELC?

Do analysts rate BMRN or CELC?

Which has higher earnings & valuation, BMRN or CELC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools